Abstract: A medicament composition for the administration to pets is provided. The composition generally includes a film, a medicament and a flavoring composition that renders the film palatable to a pet.

Abstract: The disclosure describes biodegradable stents and methods for selectively guided tissue regeneration in treating a periodontal defect adjacent to a root of a tooth. The biodegradable stents and methods have a coronal portion and a transverse portion or shelf, which reduce unwanted migration of gingival epithelium, gingival connective tissue, and soft tissue and enable the cementum and periodontal ligament cells to re-establish the periodontal ligament in a proper sequence resulting in a new periodontal attachment.

Abstract: A composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core. The polymer may include covalently linked poly(ethylene glycol) chains, and the mucoadhesive coating may be selected to facilitate transfer of the particle through the intestinal mucosa. A molecular weight and cross-link density of the polymer may be selected such that the polymer core will decompose in a predetermined time interval. The fraction of the dose of the drug entering the system at circulation during the predetermined time interval may be between about 0.25% and about 25%. The composition may be formulated as a plurality of nanoparticles or microparticles that are combined with a pharmaceutically acceptable carrier to produce an edible or inhalable drug product.

Abstract: The present invention discloses a composite collagen sponge and the preparation method thereof. The composite collagen sponge comprises collagen, cell growth factors, and a protecting agent, and has a water absorption capacity of more than 52 times. The preparation method includes a cation chromatographic purification step and a two-stage inactivation step consisting of organic solvent/detergent virus inactivation and dry heat virus inactivation. The composite collagen sponge obtained by the method of the present invention not only improves the safety and performance of the product in clinical applications, but also ensures the stability and the bioactivity throughout the effective life of the product.

Abstract: An integrated iontophoresis skin-worn patch and method for delivering a therapeutically effective amount of a corticosteroid drug compound in a systemically-safe and skin-safe manner for site-specific treatment of inflammation pain is disclosed.

Abstract: The invention relates to chewing gums for the delivery of nicotine, wherein the average pH in the mouth of individuals chewing the chewing gum, in the time period from 3 to 7 minutes from the onset of chewing, is within the interval of 8.5 to 9.

Abstract: The invention is intended to provide an adhesive patch which contains a drug except bisoprolol and which effectively inhibits the occurrence of oozing out or sticking out of the adhesive layer components from the exposed area of the adhesive layer of the adhesive patch during storage as well as the occurrence of oozing out of the drug from the adhesive layer thereby preventing the reduction in drug content. The support, the release liner and the adhesive layer constituting the adhesive patch each are formed to have a rectangular planar shape and the entire adhesive patch are formed to have a rectangular planar shape, and a protrudent part is formed on the support-side surface of the adhesive patch at a corner thereof. In addition, the adhesive patch may be formed to have a middle part and a peripheral part, and the protrudent part may be formed at a corner of the rectangular middle part.

Abstract: A diagnostic tool and method are provided wherein a faulty part and its part number is determined based on a retrieved DTC for a specific vehicle. The part number may include the original manufacturer's number and a generic equivalent manufacturer's number (if available). The diagnostic tool can search a parts database of various parts suppliers for their pricing and location. The diagnostic tool can also provide suggested fixes to the user based on the retrieved DTC.

Abstract: A hemostatic device includes a dissolvable coating and a hemostatic substance enclosed within the coating. The device can have, for example, a generally spherical shape. The hemostatic substance can be particles that take any shape, such as spherical, flat sheets, cubes, or other regular or irregular shapes of any size or volume that can be used on or within a body.

Abstract: Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases.

Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the hormone estradiol, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.

Abstract: An oral care composition is described for use in the treatment or alleviation of the symptoms of dry mouth comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient.

Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.

Abstract: An oral care device is described for contacting or transferring a dental composition to the hard or soft surfaces of the teeth comprising a backing layer and a discontinuous pattern of a dentally therapeutic composition. A method of using said oral care device to effectuate an aesthetic or therapeutic treatment is also described, whereby the oral care device is placed against the surface of at least one oral cavity structure, the discontinuous pattern of dentally therapeutic composition is contacted with or transferred to said structure. The backing layer may be left in place during the treatment period, or optionally removed from the oral cavity while leaving the therapeutic composition in contact with the target structure.

Abstract: Provided is an acellular mammalian tooth-shaped scaffold including a compound that is chemotactic, osteogenic, dentinogenic, amelogenic, or cementogenic. Also provided is a method of replacing a tooth in the mouth of a mammal, where the tooth is absent and a tooth socket is present in the mouth at the position of the absent tooth. The method includes implanting an acellular scaffold having the shape of the missing tooth into the tooth socket. Additionally, a method of making a tooth scaffold is provided. The method includes synthesizing an acellular scaffold in the shape of a mammalian tooth and adding at least one compound that is chemotactic, osteogenic, dentinogenic, amelogenic, or cementogenic.

Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.

Abstract: A water-swellable linear polymer is made by reacting together a polyethylene oxide of number average molecular weight less than 4,000, an aliphatic diol, and a difunctional diisocyanate. Controlled release composition comprises the polymer together with an active agent. The polymer is able to take up pharmaceutically active agents of molecular weight 200 to 20,000.

Abstract: The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.

Abstract: A dissolving oral adhering disc (troche) with a dimple on at least one side to improve adhesion to hard convex surfaces in the mouth, including teeth, orthodontic braces, and gums (keratinized gingiva). The disc may be designed to prevent or treat a sore in the mouth opposite a tooth or brace and/or to release a medication into the mouth, to treat such as sore or to treat or prevent conditions elsewhere in the mouth or throat or stomach.

Abstract: The invention relates to a dental implant, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterized in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component.

Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.

Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Abstract: The invention relates to plastics which are self-disinfecting. The invention relates in particular to polyether or silicone based dental plastics and impression materials in which a biocidal material is incorporated. The dental impression material ace. to the invention comprises at least a polymerizable base paste BP and a non-aqueous catalyst paste CP, wherein the base paste BP comprises about 0.001 to about 10% by weight of a water-stable anti-microbial agent. Preferred anti-microbial agents are selected from the group consisting of Hexitidin, Cetypyridininumcloride (CPC), Chlorhexidine and its derivates (CHX) and Triclosan.

Abstract: The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Abstract: The invention relates to pharmaceutical compositions suitable for oral administration in the form of edible films comprising diclofenac.

Abstract: The invention relates to a mucoadhesive medicinal preparation for administering active substances in veterinary or humane medicine, containing at least one active substance, which preparation is characterized in that it is a mucoadhesive matrix disintegratable in aqueous media, which matrix contains at least one matrix-forming polymer and wherein at least one active substance is dissolved or dispersed, and in that the said preparation disintegrates or erodes within maximally 15 minutes after introduction in an aqueous medium or in body fluids, or in that the preparation initially gels within maximally 15 min after its introduction in an aqueous medium or in body fluids, and disintegrates or erodes within maximally 30 min after said introduction.

Abstract: An oral composition for at least one or treating and inhibiting an oral inflammatory condition comprising: a Camellia extract including at least about 30% epigallocatechin gallate, at least about 50% total catechins, and at least about 60% total polyphenols; and a substantially water insoluble non-cationic anti-bacterial agent.

Abstract: A method for producing individually dosed active substance-containing and, in particular, aromatic-containing, film-shaped administration form, rapidly disintegrating upon contact with a liquid, wherein the aromatic is present as an internal, liposoluble phase in the form of liquid droplets distributed within an outer, solid but water-soluble phase, is characterized in that the said outer phase contains: at least 40% (w/w) polyvinyl alcohol 0 to 30% (w/w), of a surface-active substance, and that the constituent amount of the inner phase, relative to the outer phase, is between 0.1 and 30% (w/w), in each case relative to the water-free portions.

Abstract: Compositions and methods are directed to antimicrobial compositions and articles that release .NO from the composition and/or article in an amount effective to prevent gingival and other oral mucosal diseases.

Abstract: A composition containing therapeutic agents and/or breath freshening agents for use in the oral cavity is disclosed. The carrier comprises water-soluble polymers in combination with certain ingredients and provides a therapeutic and/or cosmetic effect. The film is coated and dried utilizing existing coating technology and exhibits instant wettability followed by rapid dissolution/disintegration upon administration in the oral cavity.

Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

Abstract: The invention relates to an orally administrable mucoadhesive film which comprises one or more bioactive ingredients and, as a major film-forming polymer, at least one alginate which is capable of forming a low viscosity aqueous solution. Also provided is a process for preparing such films.

Abstract: A polymer and a method for its preparation are provided. The polymer comprises poly(lactide), poly(lactide/glycolide) or poly(lactic acid/glycolic acid) segments bonded by ester linkages to both ends of an alkanediol core unit. The polymer is for use in a controlled release formulation for a medicament, preferably leuprolide acetate. The controlled release formulation is administered to a patient as a subcutaneous depot of a flowable composition comprising the polymer, a biocompatible solvent, and the medicament. Controlled release formulations comprising the polymer release leuprolide for treatment of prostate cancer patients over periods of 3-6 months.

Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.

Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.

Abstract: A dental dressing to promote healing and relieve pain and swelling associated with exposed dental alveoli. The dressing includes a three-dimensional dressing matrix to absorb leaked fluid associated with one or more exposed alveoli, and a therapeutic member to provide substantially localized cold therapy to one or more exposed alveoli, the therapeutic member embedded substantially within the dressing matrix and shaped to substantially engage one or more exposed alveoli while fitting substantially between contiguous teeth. At least part of the dressing matrix substantially conforms to one or more exposed alveoli, thereby engaging the therapeutic member with one or more exposed alveoli.

Abstract: A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.

Abstract: Described herein are methods of treating diseases or conditions such as incontinence, primary nocturnal enuresis (PNE), nocturia, and central diabetes insipidus, by administering desmopressin acetate in an orodispersiblc solid dosage form that disintegrates in the mouth within 10 seconds and includes an amount of desmopressin acetate, measured as the free base, of from 10 to 600 ?g.

Abstract: A method and apparatus for reducing or eliminating pain after surgical procedures related to mucosal tissue, including tonsillectomy, adenoidectomy, or other pharyngeal operations. Certain embodiments provide a biodegradable film or covering that serves as a mechanical barrier to reduce pain caused, for example, by friction between solid food and healing tissue in the first few days after surgery. Some embodiments may include one or more therapeutic substances for locally reducing pain, facilitating healing and/or otherwise treating mucosal tissue at or near a tonsil bed.

Abstract: Methods and products are provided for treating a wound or infection in a mammal or disinfecting a surface with a hypochlorous acid solution that has been activated by a catalyst. Additionally provided is a process for preparing an antimicrobial product that produces an activated hypochlorous acid solution for use as an antimicrobial.

Abstract: Compositions of fluorapatite derivative crystals are disclosed herein. Also disclosed are methods of using these compositions to treat tooth sensitivity, to use as an anticaries treatment, to use as a restorative material, to use as a tooth surface whitener, and to combat or lessen the side effects of tooth whitening.

Abstract: Water-soluble, solid, film-shaped preparations comprising at least one film-forming polymer selected from the group consisting of the fully and partially hydrolyzed polyvinyl alcohols, and at least one water-insoluble, oily liquid which is incorporated into the film-forming polymer and amounts to at least 30 percent by weight, relative to the dry portion of the preparation. Methods for producing the preparations and the use thereof are also provided.

Abstract: A retraction material promoting both retraction and drying of the gingival sulcus around a tooth. The retraction material comprises an astringent and an absorbing or drying agent. The retraction material is placed with a syringe and capsule around the gingival sulcus prior to the taking of an impression in a dental procedure.

Abstract: A composition is provided, wherein the composition comprises a water-swellable, water-insoluble polymer, a blend of a hydrophilic polymer with a complementary oligomer capable of hydrogen or electrostatic bonding to the hydrophilic polymer. The composition also includes a backing member. Active ingredients, such as a whitening agent, may be included. The composition finds utility as an oral dressing, for example, a tooth whitening composition that is applied to the teeth in need of whitening. The composition can be designed to be removed when the degree of whitening has been achieved or left in place and allowed to erode entirely. In certain embodiments, the composition is translucent. Methods for preparing and using the compositions are also disclosed.

Abstract: Denture adhesive compositions having good hold and improved taste containing a salt of a copolymer of alkyl vinyl ether-maleic acid or anhydride. Compositions containing from about 25% to about 45%, by weight of the composition, of a salt of a copolymer of alkyl vinyl ether-maleic acid or anhydride containing a cationic salt function containing: i) from about 60% to about 72% cations selected from calcium, strontium, magnesium, or combinations thereof; ii) from 0% to about 10% sodium cations; iii) less than 1% zinc cations; and iv) from about 25% to about 40% of a free acid component; and further containing from about 15% to about 25%, by weight of the composition of a carboxymethyl cellulose having a molecular weight of from about 200,000 to about 1,000,000 daltons; and a carrier. Methods of improving the adhesion of dentures to the oral cavity by applying such compositions to dentures, the oral cavity, or both, and thereafter securing the denture to the ridge or palate of the oral cavity.

Abstract: The present invention is directed to a U-shaped patch for oral health care, comprising a thin film layer and a support layer, and the inner and outer margin of the U-shaped patch have at least one notch or cut line so that the patch can be folded as a three-dimensional concave shape, wherein the thin film layer comprises a health care agent. The present invention uses a two-layered design comprising a thin film layer and a support layer, and a health care agent in the adhesive layer effective for caries prevention, whitening and/or remineralization. The patch of the present invention can closely cover teeth with the thin film layer to enable the health care agent to tightly contact the teeth so as to increase the efficacy on tooth care.